Abstract
Background: Narcolepsy, also known as Gélineau syndrome, is a chronic and neurological disease that affects 0.05% of the European population, though that percentage could be higher due to the diagnostic difficulties. The main symptom is excessive daytime sleepiness, although it may be accompanied by cataplexy, sleep paralysis and hypnagogic hallucinations.
Objective: Nowadays, there is no cure for narcolepsy, and the treatment is symptomatic; psychostimulants for sleepiness by means of amphetamines, methylphenidate, or modafinil, and antidepressants and sodium oxybate for treating cataplexy.
Methods: This is a short review regarding pharmacotherapy for narcolepsy.
Results: Hypocretins were discovered in 1998. They are neuropeptides whose deficiency is responsible for this symptomatology, which has opened up a new field of investigation.
Conclusion: Agonists of hypocretins could be a promising therapy against this disease.
[1]
NHS. Narcolepsy. Available from: https://www.nhs.uk/conditions/narcolepsy/ (Accessed on: May 10, 2021).
[2]
Orphanet. The portal for rare diseases and orphan drugs. Available from: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=2073 (Accessed on: Mar 16, 2021).
[3]
Barateau, L.; Dauvilliers, Y. Recent advances in treatment for narcolepsy. Ther. Adv. Neurol. Disord., 2019, 12, 1756286419875622.
[http://dx.doi.org/10.1177/1756286419875622] [PMID: 31632459]
[http://dx.doi.org/10.1177/1756286419875622] [PMID: 31632459]
[4]
Deflandre, E.; Roelants, F.; Cambron, L.; Poirrier, R. Narcolepsy-cataplexy. Rev. Med. Liege, 2002, 57(8), 519-527.
[PMID: 12405025]
[PMID: 12405025]
[5]
Burk, J.A.; Fadel, J.R. The orexin/hypocretin system: Functional roles and therapeutic potential, 1st ed; Academic Press: United Kingdom, 2019.
[6]
Lin, L.; Faraco, J.; Li, R.; Kadotani, H.; Rogers, W.; Lin, X.; Qiu, X.; de Jong, P.J.; Nishino, S.; Mignot, E. The sleep disorder canine nar-colepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 1999, 98(3), 365-376.
[http://dx.doi.org/10.1016/S0092-8674(00)81965-0] [PMID: 10458611]
[http://dx.doi.org/10.1016/S0092-8674(00)81965-0] [PMID: 10458611]
[7]
Pedersen, N.W.; Holm, A.; Kristensen, N.P.; Bjerregaard, A-M.; Bentzen, A.K.; Marquard, A.M.; Tamhane, T.; Burgdorf, K.S.; Ullum, H.; Jennum, P.; Knudsen, S.; Hadrup, S.R.; Kornum, B.R. CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens. Nat. Commun., 2019, 10(1), 837.
[http://dx.doi.org/10.1038/s41467-019-08774-1] [PMID: 30783092]
[http://dx.doi.org/10.1038/s41467-019-08774-1] [PMID: 30783092]
[8]
National Center for Biotechnology Information. PubChem Database. Pitolisant, CID=9948102. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Pitolisant (Accessed on: August 28, 2021).
[9]
Esbenshade, T.A.; Browman, K.E.; Bitner, R.S.; Strakhova, M.; Cowart, M.D.; Brioni, J.D. The histamine H3 receptor: An attractive target for the treatment of cognitive disorders. Br. J. Pharmacol., 2008, 154(6), 1166-1181.
[http://dx.doi.org/10.1038/bjp.2008.147] [PMID: 18469850]
[http://dx.doi.org/10.1038/bjp.2008.147] [PMID: 18469850]
[10]
European Medicines Agency. Public summary of positive opinion for orphan designation of 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride
for the treatment of narcolepsy. 2016. Available from: http://www.ema.europa.eu (Accessed on: June 14, 2016).
[11]
Szakacs, Z.; Dauvilliers, Y.; Mikhaylov, V.; Poverennova, I.; Krylov, S.; Jankovic, S.; Sonka, K.; Lehert, P.; Lecomte, I.; Lecomte, J.M.; Schwartz, J.C. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: A randomised, double-blind, placebo-controlled trial. Lancet Neurol., 2017, 16(3), 200-207.
[http://dx.doi.org/10.1016/S1474-4422(16)30333-7] [PMID: 28129985]
[http://dx.doi.org/10.1016/S1474-4422(16)30333-7] [PMID: 28129985]
[12]
Investigational Narcolepsy Treatment TAK-925 Demonstrates Safety, Effectiveness. Available from: https://www.neurologylive.com/view/investigationalnarcolepsy-tak-925-demonstrates-safety-effectiveness (Accessed on June 13, 2021).
[13]
Takeda. New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor
(OX2R) Agonist, in Patients with Narcolepsy Type 1. 2019. Available from: https://www.takeda.com/newsroom/newsreleases/2019/new-data-presented-at-world-sleep-congress-demonstrate-early-signs-of-efficacy-for-tak-925-a-selective-orexin-type-2-receptor-ox2r-agonist-in-patients-with-narcolepsy-type-1/ (Accessed on June 13, 2021).
[14]
NIH. A Study of TAK-994 in Adults With Narcolepsy. A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal
Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy
(Narcolepsy Type 1). Available from: https://ichgcp.net/es/clinical-trials-registry/NCT04820842
[15]
Pellitteri, G.; de Biase, S.; Valente, M.; Gigli, G.L. How treatable is narcolepsy with current pharmacotherapy and what does the future hold? Expert Opin. Pharmacother., 2021, 22(12), 1517-1520.
[http://dx.doi.org/10.1080/14656566.2021.1915987] [PMID: 33882765]
[http://dx.doi.org/10.1080/14656566.2021.1915987] [PMID: 33882765]
Article Metrics
13
1